ORX Share Price Performance
SEK 16.48
-2.80 (-14.52%)
43.2% undervalued intrinsic discount
SEK 29.00
Fair Value
Price SEK 16.48
AnalystConsensusTarget SEK 29.00
Fair ValueSEK 29.00
Share Pricen/a
Orexo AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
ORX Community Narratives
AN
Fair Value
·Fair Value SEK 29 43.2% undervalued intrinsic discount
ORX: Relocation And In-Vivo Results Will Support Measured Opportunity Ahead
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
ORX: Relocation And In-Vivo Results Will Support Measured Opportunity Ahead
Orexo looks like it’s moving from uncertainty to steadier footing as a key legal dispute is settled and its main product’s sales become easier to plan around. The next chapter hinges on whether new drug candidates and digital therapy partnerships can turn early trial momentum into real launches—before supply, legal, and rule-change risks slow things down.Read more
AN
SEK 29
43.2% undervalued intrinsic discount
Fair Value
Profit Margin
19.84%
Future PE
188.15x
Price in 2029
SEK 33.51
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
ORX: Overdose Reversal Pipeline Progress Will Support Future Upside
Fair Value: SEK 29 43.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Orexo AB (publ) Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 22, 2026
- -12.11
- 37.95%
- -2,548.19%
- 0%
About ORX
- Founded
- 1994
- Employees
- 61
- CEO
- WebsiteView website
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
